Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Analysis of the Main Checkpoints of the Jnk-Mapk Pathway in Htlv-1-Associated Leukemia/Lymphoma Via Boolean Network Simulation Publisher



S Mardi SHAYAN ; A Letafati ARASH ; A Hosseini AMIN ; R Faraji REZA ; P Hosseini PARASTOO ; Sh Mozhgani Sayed HAMIDREZA
Authors

Source: Biochemical Genetics Published:2024


Abstract

The c-Jun N-terminal kinase (JNK) pathway is a signal transduction pathway that plays a critical role in cell growth and survival. Its dysregulation is related to various cancers, including adult T-cell leukemia/lymphoma (ATLL), an aggressive peripheral T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1) infection. There is currently no vaccine or definitive treatment for ATLL. This research aimed to identify the JNK-MAPK pathway checkpoints to identify possible therapeutic targets using Boolean network analysis. First, the genes involved in the JNK pathway and their interactions were identified and mapped. Next, a Boolean network analysis was performed using the R programming language, which suggested protein kinase B (AKT) and MAP kinase phosphatase (MKP) for further evaluation. Finally, to confirm the effect of these two genes, a clinical study was conducted among ATLL patients and healthy individuals. The quantitative real time polymerase chain reaction (qRT‒PCR) results revealed a statistically significant decrease in the expression of AKT and MKP in ATLL patients compared to normal controls. This highlights the potential role of these two genes as potential therapeutic targets in ATLL. © 2024 Elsevier B.V., All rights reserved.
Other Related Docs
7. Toll-Like Receptor Pathway and Its Targeting in Treatment of Cancers, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
17. Toll-Like Receptor Pathway and Its Targeting in Treatment of Cancers, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers (2015)